Pill Identifier App

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

-- Worldwide Operational Sales Increased 10.5 Percent -- -- Worldwide Medical Products Operational Sales Increased 27.0 Percent -- -- International Pharmaceutical Operational Sales Increased 13.8 Percent -- -- U.S. Nutritional Sales Increased 10.0 Percent --

ABBOTT PARK, Ill., July 15 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2009.

  --  Diluted earnings per share, excluding specified items, were $0.89, at
      the high end of Abbott's second-quarter guidance range of $0.87 to
      $0.89. Diluted earnings per share under Generally Accepted Accounting
      Principles (GAAP) were $0.83.
  --  Worldwide operational sales, which excludes an unfavorable 8.0 percent
      effect of exchange rates, increased 10.5 percent. Reported sales,
      including the impact of exchange, increased 2.5 percent. Excluding the
      expected decline in Depakote  sales due to generic competition,
      worldwide operational sales increased 14.6 percent.
  --  Worldwide medical products operational sales, which excludes an
      unfavorable 9.5 percent effect of exchange rates, increased 27.0
      percent. Worldwide operational vascular sales increased 43.0 percent
      driven by the continued success of the XIENCE V  drug-eluting stent
      (DES).
  --  Worldwide pharmaceutical operational sales, which excludes an
      unfavorable 8.3 percent effect of exchange rates, increased 4.0
      percent. Excluding the impact of Depakote, worldwide pharmaceutical
      operational sales increased 11.4 percent. Worldwide HUMIRA 
      operational sales increased 32.8 percent, which excludes an
      unfavorable 12.4 percent effect of exchange rates. U.S. HUMIRA sales
      were $635 million, up 20.9 percent.
  --  Worldwide nutritional operational sales, which excludes an unfavorable
      5.2 percent effect of exchange rates, increased 9.2 percent. U.S.
      nutritional sales increased 10.0 percent, driven by market share gains
      in the infant formula business.

  --  Submitted CERTRIAD(TM), the fixed-dose combination of TRILIPIX  and
      CRESTOR , for U.S. regulatory approval and received CE Mark for XIENCE
      PRIME(TM), both ahead of the company's forecast.


"We achieved our performance goals for the quarter, with results at the high end of our previous expectations," said Miles D. White, chairman and chief executive officer, Abbott. "Our diverse mix of market-leading products and global businesses delivered double-digit operational sales growth, with strong performance from our key growth drivers."

  The following is a summary of second-quarter 2009 sales.




  Quarter Ended 6/30/09
  (dollars in millions)                           % Change vs. 2Q08
                                                        Foreign
                                     Sales Operational  Exchange    Reported

  Total Sales                       $7,495      10.5(a)   (8.0)      2.5

      Total International Sales     $3,932      15.6     (14.9)      0.7

      Total U.S. Sales              $3,563       4.5(a)     --       4.5

  Worldwide Pharmaceutical Sales    $3,946       4.0(a)   (8.3)     (4.3)

      International Pharmaceuticals $1,993      13.8     (16.7)     (2.9)

      U.S. Pharmaceuticals          $1,953      (5.6)(a)    --      (5.6)

  Worldwide Nutritional Sales       $1,283       9.2      (5.2)      4.0

      International Nutritionals      $615       8.4     (10.3)     (1.9)

      U.S. Nutritionals               $668      10.0        --      10.0

  Worldwide Diagnostics Sales         $878       3.9     (10.1)     (6.2)

      International Diagnostics       $642       3.8     (13.3)     (9.5)

      U.S. Diagnostics                $236       4.1        --       4.1

  Worldwide Vascular Sales            $658      43.0      (8.7)     34.3

       International Vascular         $263      12.4     (15.6)     (3.2)

       U.S. Vascular                  $395      81.1        --      81.1

  Other Sales                        $730(b)    44.8(b)   (7.3)     37.5

  Note:  See "Consolidated Statement of Earnings" for more information.

  (a) Sales comparison reflects the expected impact of generic Depakote
      competition. See Q&A Answer 1 for further discussion.
  (b) Includes the acquisition of Advanced Medical Optics, which closed on
      Feb. 25, 2009.



  The following is a summary of first-half 2009 sales.

  First-Half Ended 6/30/09
  (dollars in millions)                            % Change vs. 1H08
                                                         Foreign
                                    Sales   Operational  Exchange   Reported
  Total Sales                      $14,213       8.0(a)   (7.1)       0.9

      Total International Sales     $7,648      13.3     (13.0)       0.3

      Total U.S. Sales              $6,565       1.7(a)     --        1.7

  Worldwide Pharmaceutical Sales    $7,582       2.5(a)   (7.5)      (5.0)

      International Pharmaceuticals $4,102      13.0     (14.3)      (1.3)

      U.S. Pharmaceuticals          $3,480      (9.0)(a)    --       (9.0)

  Worldwide Nutritional Sales       $2,465       9.8      (4.7)       5.1

      International Nutritionals    $1,190      12.7      (9.6)       3.1

      U.S. Nutritionals             $1,275       7.1        --        7.1

  Worldwide Diagnostics Sales       $1,694       4.9      (9.0)      (4.1)

      International Diagnostics     $1,237       4.9     (12.0)      (7.1)

      U.S. Diagnostics                $457       4.7        --        4.7

  Worldwide Vascular Sales          $1,302      45.0      (6.7)      38.3

       International Vascular         $513      13.1     (12.4)       0.7

       U.S. Vascular                  $789      82.6        --       82.6

  Other Sales                       $1,170(b)   17.9(b)   (6.3)      11.6

  Note:  See "Consolidated Statement of Earnings" for more information.

  (a) Sales comparison reflects the expected impact of generic Depakote
      competition. See Q&A Answer 1 for further discussion.
  (b) Includes the acquisition of Advanced Medical Optics, which closed on
      Feb. 25, 2009.



  The following is a summary of Abbott's second-quarter 2009 sales for
  selected products.

  Quarter Ended 6/30/09
  (dollars in millions)
                        U.S.                     International
                           % Change                 % Change vs. 2Q08
                               vs.                        Foreign
                   Sales      2Q08     Sales  Operational Exchange Reported
  Pharmaceutical
   Products

    HUMIRA          $635      20.9      $676      44.0     (24.0)    20.0

    Kaletra         $111      (8.0)     $232      13.9     (15.1)    (1.2)

    TriCor/TRILIPIX $336       9.1        --        --        --       --

    Niaspan         $208       6.9        --        --        --       --

    Lupron          $137      68.5       $60       1.9     (18.7)   (16.8)

    Synthroid        $97     (16.0)      $19       1.4     (18.6)   (17.2)

    Depakote(a)      $80     (79.3)      $22      (0.4)    (19.3)   (19.7)

  Nutritional Products

    Pediatric
     Nutritionals   $329       6.0      $354      11.7      (8.1)     3.6

    Adult
     Nutritionals   $326      12.0      $262       4.5     (12.9)    (8.4)

  Medical Products

    Core
     Laboratory
     Diagnostics    $154      (2.3)     $593       2.9     (13.1)   (10.2)

    Coronary Stents $256     225.8      $141      19.7     (17.5)     2.2

    Diabetes Care   $128      (4.8)     $181       7.4     (17.9)   (10.5)

    Medical Optics  $100       n/m      $165       n/m       n/m      n/m

    Molecular
     Diagnostics     $36      23.8       $37      18.0     (17.4)     0.6

  (a) Sales comparison reflects the expected impact of generic Depakote
      competition.
  Note: The impact of foreign exchange on global sales can be found on the
  subsequent page.
  n/m = Not meaningful



  The following summarizes the impact of foreign exchange on global sales
  for selected products.

  Quarter Ended 6/30/09
  (dollars in millions)
                                                      Global Sales
                                                   % Change vs. 2Q08
                                     Global              Foreign
                                     Sales  Operational  Exchange   Reported
  Pharmaceutical Products

    HUMIRA                          $1,311      32.8     (12.4)      20.4

    Kaletra                           $343       6.5     (10.0)      (3.5)

    TriCor/TRILIPIX                   $336       9.1        --        9.1

    Niaspan                           $208       6.9        --        6.9

    Lupron                            $197      37.1      (8.8)      28.3

    Synthroid                         $116     (13.1)     (3.1)     (16.2)

    Depakote(a)                       $102     (74.0)     (1.3)     (75.3)

  Nutritional Products

    Pediatric Nutritionals            $683       8.9      (4.2)       4.7

    Adult Nutritionals                $588       8.3      (6.4)       1.9

  Medical Products

    Core Laboratory Diagnostics       $747       1.9     (10.6)      (8.7)

    Coronary Stents                   $397      94.6     (11.1)       83.5

    Diabetes Care                     $309       2.6     (10.8)      (8.2)

    Medical Optics                    $265       n/m       n/m        n/m

    Molecular Diagnostics              $73      20.6      (9.6)      11.0

  (a) Sales comparison reflects the expected impact of generic Depakote
      competition.
  n/m = Not meaningful



  The following is a summary of Abbott's first-half 2009 sales for selected
  products.

  First-Half Ended 6/30/09
  (dollars in millions)
                        U.S.                      International
                           % Change                  % Change vs. 1H08
                               vs.                        Foreign
                   Sales      1H08     Sales  Operational Exchange Reported
  Pharmaceutical
   Products

    HUMIRA        $1,045      12.7    $1,290      46.4     (22.3)    24.1

    Kaletra         $195     (16.3)     $440       6.1     (13.6)    (7.5)

    TriCor/
     TRILIPIX       $588       6.4        --        --        --       --

    Lupron          $270       n/m      $120       5.5     (18.1)   (12.6)

    Niaspan         $386       4.2        --        --        --       --

    Depakote(a)     $190     (73.8)      $42      (0.5)    (19.0)   (19.5)

    Synthroid       $182     (12.6)      $38       5.9     (20.4)   (14.5)

  Nutritional
   Products

    Pediatric
     Nutritionals   $624       1.4      $690      16.4      (7.7)     8.7

    Adult
     Nutritionals   $614       9.2      $500       8.1     (11.9)    (3.8)

  Medical Products

    Core
     Laboratory
     Diagnostics    $299      (0.6)   $1,143       4.0     (11.8)    (7.8)

    Coronary Stents $524     240.2      $275      23.0     (13.6)     9.4

    Diabetes Care   $248      (8.5)     $345       4.2     (16.0)   (11.8)

    Medical Optics  $145       n/m      $165       n/m       n/m      n/m

    Molecular
     Diagnostics     $70      18.8       $70      21.8     (16.2)     5.6


  (a) Sales comparison reflects the expected impact of generic Depakote
  competition.
  Note: The impact of foreign exchange on global sales can be found on the
  subsequent page.
  n/m = Not meaningful



  The following summarizes the impact of foreign exchange on global sales
  for selected products.

  First-Half Ended 6/30/09
  (dollars in millions)
                                                     Global Sales
                                                  % Change vs. 1H08
                                     Global             Foreign
                                     Sales  Operational Exchange   Reported
  Pharmaceutical Products

    HUMIRA                          $2,335      30.6     (11.8)     18.8

    Kaletra                           $635      (1.3)     (9.1)    (10.4)

    TriCor/TRILIPIX                   $588       6.4        --       6.4

    Lupron                            $390      89.8     (11.4)     78.4

    Niaspan                           $386       4.2        --       4.2

    Depakote(a)                       $232     (68.9)     (1.3)    (70.2)

    Synthroid                         $220      (9.3)     (3.6)    (12.9)

  Nutritional Products

    Pediatric Nutritionals          $1,314       9.0      (3.9)      5.1

    Adult Nutritionals              $1,114       8.6      (5.7)      2.9

  Medical Products

    Core Laboratory Diagnostics     $1,442       3.1      (9.5)     (6.4)

    Coronary Stents                   $799     105.4      (8.4)     97.0

    Diabetes Care                     $593      (0.9)     (9.5)    (10.4)

    Medical Optics                    $310       n/m       n/m       n/m

    Molecular Diagnostics             $140      20.4      (8.6)     11.8

  (a) Sales comparison reflects the expected impact of generic Depakote
  competition.
  n/m = Not meaningful


  Business Highlights

  --  Initiated Trial of Next-Generation XIENCE PRIME(TM) Drug-Eluting
      Stent: Announced CE Mark for Abbott's next-generation XIENCE PRIME
      Everolimus Eluting Coronary Stent System for the treatment of coronary
      artery disease. Abbott is launching XIENCE PRIME in a broad size
      matrix with lengths up to 38 mm in Europe in the third quarter. Abbott
      also announced the initiation of SPIRIT PRIME, a clinical trial to
      study the performance of XIENCE PRIME. Results from SPIRIT PRIME will
      be used to support the regulatory filing for XIENCE PRIME in the
      United States.
  --  Presented Five-Year Data on HUMIRA : Data presented at the European
      League Against Rheumatism (EULAR) annual congress showed that patients
      with moderate to severe early rheumatoid arthritis (RA) initially
      treated with the combination of HUMIRA and methotrexate (MTX) for two
      years had greater inhibition of radiographic progression at five years
      than patients initially treated with either of the monotherapies.
  --  Presented TRILIPIX  Combination Data in Diabetic Subset: Announced
      that TRILIPIX (fenofibric acid) delayed-release capsules in
      combination with rosuvastatin calcium achieved individual and combined
      lipid targets in patients with mixed dyslipidemia and type 2 diabetes.
      In these patients, the combination of TRILIPIX and rosuvastatin helped
      up to three times more patients simultaneously reach all three key
      lipid targets - HDL, triglycerides and LDL - than the pre-determined
      monotherapy. These results were presented at the American Diabetes
      Association's 2009 Scientific Sessions.
  --  Extended Lipid Management Relationship with AstraZeneca: Announced an
      agreement for AstraZeneca to co-promote Abbott's TRILIPIX (fenofibric
      acid). AstraZeneca is now co-promoting TRILIPIX alongside Abbott in
      the United States. Abbott also promotes AstraZeneca's CRESTOR  in the
      United States.
  --  Submitted New Drug Application to the FDA for CERTRIAD(TM): Abbott and
      AstraZeneca announced that the companies submitted a New Drug
      Application (NDA) to the U.S. Food and Drug Administration (FDA) for
      CERTRIAD, the fixed-dose combination of TRILIPIX and CRESTOR
      (rosuvastatin) for the treatment of mixed dyslipidemia. The NDA
      submission is supported by data from multiple studies, including
      efficacy and safety studies with the 5 mg, 10 mg and 20 mg doses of
      rosuvastatin combined with fenofibric acid.
  --  Presented XIENCE V  Data from SPIRIT V at EuroPCR: Announced one-year
      results from our SPIRIT V post-approval, single-arm study of Abbott's
      drug-eluting stent, XIENCE V. Results showed an impressively low 1.8
      percent rate of repeat procedure (target lesion revascularization), a
      0.7 percent rate of stent thrombosis and a 5.1 percent rate of major
      adverse cardiac events (MACE) at one year in patients treated with
      XIENCE V.

  --  Added Hepatitis B Test to Broad Menu of Immunoassays on the ARCHITECT 
      i 2000 and i 2000SR: Launched ARCHITECT  CORE(TM) in the United
      States, an automated hepatitis B test for use on its ARCHITECT i 2000
      and i 2000SR immunoassay testing instruments. Hepatitis B is a liver
      disease caused by the hepatitis B virus (HBV). It ranges in severity
      from a mild illness, lasting a few weeks (acute), to a serious
      long-term (chronic) illness that can lead to liver disease or liver
      cancer.


  Abbott confirms double-digit earnings-per-share growth outlook for 2009

Abbott is confirming previously issued earnings-per-share guidance for the full-year 2009 of $3.65 to $3.70 under both Generally Accepted Accounting Principles (GAAP) and on a non-GAAP, or adjusted basis. The midpoint of this 2009 guidance range reflects double-digit growth over 2008 earnings per share.

Abbott is also providing earnings-per-share guidance for the third-quarter 2009 of $0.88 to $0.90, excluding specified items. The midpoint of this guidance reflects nearly 13 percent growth over the prior year third quarter. Abbott forecasts specified items for the third-quarter 2009 of approximately $0.05 per share, primarily associated with previously announced acquisitions and cost reduction initiatives. Including these specified items, projected earnings per share under GAAP would be $0.83 to $0.85 for the third-quarter 2009.

Abbott declares quarterly dividend; double-digit increase over prior year

On June 12, 2009, the board of directors of Abbott declared the company's quarterly common dividend of 40 cents per share, an increase of 11 percent over the prior period. The cash dividend is payable Aug. 15, 2009, to shareholders of record at the close of business on July 15, 2009. This marks the 342nd consecutive dividend paid by Abbott since 1924.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com. Abbott will webcast its live second-quarter earnings conference call through its Investor Relations Web site at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

          -- Private Securities Litigation Reform Act of 1995 --
             A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

                       Abbott Laboratories and Subsidiaries
                       Consolidated Statement of Earnings
                    Second Quarter Ended June 30, 2009 and 2008
                      (in millions, except per share data)
                                   (unaudited)

                                     2009      2008     % Change

  Net Sales                         $7,495    $7,314       2.5

  Cost of products sold              3,129     3,120       0.3
  Research and development             670       657       2.0
  Acquired in-process research
   and development                      --        78       n/m
  Selling, general and
   administrative                    2,025     2,052      (1.4)
  Total Operating Cost and Expenses  5,824     5,907      (1.4)

  Operating earnings                 1,671     1,407      18.8

  Net interest expense                 103        83      23.7
  Net foreign exchange (gain) loss      14        15      (0.5)
  (Income) from TAP Pharmaceutical
   Products Inc. joint venture          --      (17)       n/m
  Other (income) expense, net          (13)     (310)      n/m        1)
  Earnings before taxes              1,567     1,636      (4.2)
  Taxes on earnings                    279       314     (11.3)

  Net Earnings                      $1,288    $1,322      (2.6)

  Net Earnings Excluding Specified
   Items, as described below        $1,388    $1,308       6.1        2)

  Diluted Earnings Per Common Share  $0.83     $0.85      (2.4)

  Diluted Earnings Per Common Share,
   Excluding Specified Items, as
   described below                   $0.89     $0.84       6.0        2)

  Average Number of Common
   Shares Outstanding Plus Dilutive
   Common Stock Options and Awards   1,551     1,553

  1) 2008 Other (income) expense, net, includes a gain of $95 million in
     connection with the closing of the TAP Pharmaceutical Products Inc.
     joint venture transaction and a gain of $52 million from the sale of
     an equity investment in Millennium Pharmaceuticals. These items have
     been treated as specified items. The remainder of Other (income)
     expense, net, is primarily related to ongoing contractual payments
     from Takeda associated with the conclusion of the TAP joint venture.

  2) 2009 Net Earnings Excluding Specified Items excludes after-tax charges
     of $33 million, or $0.02 per share, primarily for costs associated
     with the acquisition of Advanced Medical Optics (AMO) and $67
     million, or $0.04 per share, for cost reduction initiatives and
     other.  See Q&A Answer 6 for a discussion of specified items.

     2008 Net Earnings Excluding Specified Items excludes a tax-free gain
     of $95 million, or $0.06 per share, recorded on the closing of the TAP
     joint venture transaction, a reduction in income taxes of $30 million,
     or $0.02 per share, relating to the settlement of an IRS audit, and an
     after-tax gain of $40 million, or $0.03 per share, relating to the
     sale of an equity investment in Millennium Pharmaceuticals. These
     items were partially offset by after-tax charges of $61 million, or
     $0.04 per share, for acquired in-process research and development
     relating to technology investments, $45 million, or $0.03 per share,
     for cost reduction initiatives, and $45 million, or $0.03 per share,
     for acquisition integration, TAP separation and other.

  NOTE: See attached questions and answers section for further explanation
  of Consolidated Statement of Earnings line items.

  n/m = Percent change is not meaningful.



                     Abbott Laboratories and Subsidiaries
                      Consolidated Statement of Earnings
                   First Half Ended June 30, 2009 and 2008
                     (in millions, except per share data)
                                (unaudited)

                                     2009      2008     % Change

  Net Sales                        $14,213   $14,080       0.9

  Cost of products sold              6,065     6,081      (0.3)
  Research and development           1,321     1,277       3.5
  Acquired in-process research
   and development                      --        97       n/m
  Selling, general and
   administrative                    4,095     4,070       0.6
  Total Operating Cost and
   Expenses                         11,481    11,525      (0.4)

  Operating earnings                 2,732     2,555       7.0

  Net interest expense                 191       177       8.4
  Net foreign exchange (gain) loss      29        21      39.3
  (Income) from TAP Pharmaceutical
   Products Inc. joint venture          --      (119)      n/m
  Other (income) expense, net         (988)     (321)      n/m        1)
  Earnings before taxes              3,500     2,797      25.1
  Taxes on earnings                    773       537      43.9

  Net Earnings                      $2,727    $2,260      20.7

  Net Earnings Excluding Specified
   Items, as described below        $2,531    $2,296      10.2        2)

  Diluted Earnings Per Common Share  $1.75     $1.45      20.7

  Diluted Earnings Per Common Share,
   Excluding Specified Items, as
   described below                   $1.62     $1.47      10.2        2)

  Average Number of Common Shares
   Outstanding Plus Dilutive
   Common Stock Options and Awards   1,554     1,557

  1) Other (income) expense, net, in 2009 includes the derecognition of a
     contingent liability ($797 pre-tax, $505 after-tax) and ongoing
     contractual payments from Takeda associated with the conclusion of the
     TAP joint venture.  Other (income) expense, net, in 2008 includes a
     gain of $95 million in connection with the closing of the TAP
     Pharmaceutical Products Inc. joint venture transaction and a gain of
     $52 million from the sale of an equity investment in Millennium
     Pharmaceuticals. These items have been treated as specified items. The
     remainder of Other (income) expense, net, is primarily related to
     ongoing contractual payments from Takeda associated with the
     conclusion of the TAP joint venture.

  2) 2009 Net Earnings Excluding Specified Items excludes an after-tax gain
     of $505 million, or $0.32 per share, relating to the derecognition of a
     contingent liability that was recorded in connection with the
     conclusion of the TAP joint venture.  This was partially offset by
     $108 million, or $0.07 per share, primarily relating to costs
     associated with the acquisition of Advanced Medical Optics, $41
     million, or $0.02 per share, for litigation settlements and $160
     million, or $0.10 per share, for cost reduction initiatives and costs
     associated with a delayed product launch.

     2008 Net Earnings Excluding Specified Items excludes a tax-free gain of
     $95 million, or $0.06 per share, recorded on the closing of the TAP
     joint venture transaction, a reduction in income taxes of $30 million,
     or $0.02 per share, relating to the settlement of an IRS audit, and an
     after-tax gain of $49 million, or $0.03 per share, relating to sales
     of equity investments in Millennium Pharmaceuticals and Boston
     Scientific. These items were offset by after-tax charges of $76
     million, or $0.05 per share, for acquired in-process research and
     development relating to technology investments, $75 million, or
     $0.05 per share, for cost reduction initiatives, and $59 million, or
     $0.03 per share, for acquisition integration, TAP separation and other.

  NOTE: See attached questions and answers section for further explanation
  of Consolidated Statement of Earnings line items.

  n/m = Percent change is not meaningful.


  Questions & Answers

  Q1)  What drove the operational growth of worldwide pharmaceutical sales?

A1) Excluding Depakote, U.S. pharmaceutical sales increased more than 9 percent. As expected, U.S. pharmaceutical sales reflected the impact of generic competition for Depakote. This resulted in a $306 million decline in Depakote sales in the second quarter, reducing reported U.S. pharmaceutical sales growth by nearly 15 percentage points.

U.S. pharmaceutical sales were led by HUMIRA, with sales of $635 million, up 20.9 percent. Underlying demand for HUMIRA remains strong, and share gains occurred across all three major indications in the quarter. The lipid franchise continues to perform well, with TriCor/TRILIPIX sales up more than 9 percent and Niaspan sales up nearly 7 percent, both exceeding the market growth rate.

International pharmaceutical operational sales increased 13.8 percent, excluding a 16.7 percent negative impact from exchange. Internationally, operational growth for HUMIRA was 44 percent, with sales of $676 million, in line with our expectations. There was a 24-percentage point negative impact of exchange on international HUMIRA sales. International anti-TNF market growth trends remain strong, and HUMIRA maintains a market-leading position in many of the international markets, including the number one share position in Western Europe. Kaletra also performed well internationally, with operational growth of nearly 14 percent.

Q2) What drove the 27.0 percent operational increase in global medical products sales and strong global nutritional products sales?

A2) Medical products operational sales increased 27.0 percent, excluding a 9.5 percent negative impact from exchange. This includes the first full quarter of sales from Advanced Medical Optics (AMO), which was acquired during the first quarter of 2009. Strength in the quarter reflects 43 percent operational growth in worldwide vascular sales and continued double-digit growth in Abbott's molecular diagnostics business.

Vascular sales were driven by the continued successful uptake of XIENCE V, which remains the number one DES in the United States and Europe. XIENCE platform share, which includes XIENCE and Promus, is now more than half of the U.S. market. U.S. DES penetration is in the mid-70s and percutaneous coronary intervention (PCI) volumes increased in the low-single digits from the second quarter of last year.

Worldwide nutritional products operational sales increased more than 9 percent, excluding 5.2 percent negative exchange. This reflects continued strong growth in key emerging markets, including Latin America and Asia. U.S. nutritional sales increased 10.0 percent, driven by strong market share gains in the infant nutritional business.

Q3) What was the second-quarter gross margin ratio?

A3) The gross margin ratio before and after specified items is shown below (dollars in millions):

                                                         2Q09
                                           Cost of
                                           Products     Gross       Gross
                                             Sold       Margin      Margin %
  As reported                               $3,129      $4,366       58.3%
  Adjusted for specified items:
  Acquisition related                         ($17)        $17        0.2%
  Cost reduction initiatives and other        ($52)        $52        0.7%
  As adjusted                               $3,060      $4,435       59.2%

The adjusted gross margin ratio was 59.2 percent, an improvement of 80 basis points from the prior year. This gross margin expansion was driven by improved operating performance of the diagnostic and nutrition businesses, and the impact of foreign exchange. This occurred despite the negative impact from lower Depakote sales.

Q4) How did R&D and SG&A investment compare to the company's guidance?

A4) Both SG&A and R&D were in line with our forecast for the quarter. Ongoing R&D expense, excluding specified items and the impact of foreign exchange, was up nearly 6 percent, reflecting continued investment in our pipeline, including programs in vascular devices, biologics, neuroscience, oncology and HCV. Ongoing SG&A expense, excluding specified items and the impact of foreign exchange, was up nearly 5 percent, in line with our forecast for significant SG&A leverage in 2009. We are forecasting a reduction in full-year ongoing SG&A as a percentage of sales of more than 100 basis points compared to 2008.

Q5) What was the tax rate in the quarter?

A5) The tax rate this quarter was 17.8 percent, in line with the previous forecast.

  Q6)  How did specified items affect reported results?

  A6)  Specified items impacted second-quarter results as follows:





  (dollars in millions, except                           2Q09
   earnings-per-share)                         Earnings
                                           Pre-tax   After-tax        EPS
  As reported                               $1,567      $1,288       $0.83
  Adjusted for specified items:
  Acquisition related                          $40         $33       $0.02
  Cost reduction initiatives and other         $82         $67       $0.04
  As adjusted                               $1,689      $1,388       $0.89

Acquisition related is primarily associated with acquisition costs related to Advanced Medical Optics (AMO), which closed during the first quarter of 2009. Cost reduction initiatives include actions to improve efficiencies, including the previously announced efforts in the core laboratory diagnostic business.

The pre-tax impact of specified items by Consolidated Statement of Earnings line item is as follows (dollars in millions):

                                                          2Q09
                                            Cost of
                                            Products
                                              Sold         R&D        SG&A
  As reported                               $3,129        $670      $2,025
  Adjusted for specified items:
  Acquisition related                          $17          $8         $15
  Cost reduction initiatives and other         $52          $3         $27
  As adjusted                               $3,060        $659      $1,983



  Q7)  What are the key areas of focus in Abbott's broad-based pipeline?

A7) Abbott is advancing leading-edge scientific discoveries across the company, including:

  --  Lipid Management
      --  In January of this year, we launched TRILIPIX, Abbott's
          next-generation fenofibric acid.   The product has been well
          received and the launch has been in line with our expectations.
          During the second quarter, we submitted CERTRIAD for U.S.
          regulatory approval. CERTRIAD is the fixed-dose combination of
          TRILIPIX and CRESTOR that Abbott is developing with AstraZeneca.
          Also in the quarter, we expanded our relationship with AstraZeneca
          with an agreement for the company to co-promote TRILIPIX in the
          United States.
  --  Oncology
      --  Abbott's oncology pipeline includes therapies that represent
          promising, unique scientific approaches to treating cancer. Abbott
          is focused on the development of targeted, less-toxic treatments
          that inhibit tumor growth and improve response to common cancer
          therapies. Our collaboration with Genentech/Roche to develop two
          Abbott-discovered compounds continues to progress. These compounds
          include ABT-869, a multi-targeted kinase inhibitor and ABT-263, a
          Bcl-2 family protein antagonist. We now anticipate beginning a
          pivotal study for ABT-869 later this year.
      --  Abbott's oncology research also includes a PARP-inhibitor in Phase
          II, which prevents DNA repair in cancer cells, enhancing the
          effectiveness of current cancer therapies.
  --  Neuroscience
      --  Abbott is conducting innovative research in neuroscience, where we
          have developed compounds that target receptors in the brain that
          help regulate mood, memory and other neurological functions to
          address conditions such as attention deficit hyperactivity
          disorder, Alzheimer's disease and schizophrenia.
      --  We're also pursuing compounds that could provide relief across a
          broad spectrum of pain states, such as osteoarthritis,
          postoperative pain and cancer pain.
  --  Immunology
      --  Abbott's scientific experience with the anti-TNF biologic HUMIRA
          serves as a strong foundation for our continuing research in
          immunology. HUMIRA has several indications in Phase III, including
          ulcerative colitis and pediatric Crohn's disease. In addition,
          ABT-874, Abbott's anti-IL 12/23 biologic, is in Phase III for
          psoriasis and Phase II for Crohn's disease. ABT-874 is on track
          for regulatory submission in 2010 for the psoriasis indication. We
          are also working to advance development of our early discovery
          programs, including oral DMARD therapies, as well as other
          potential biologic targets.
      --  Additionally, our proprietary DVD-Ig technology represents an
          innovative approach that can target multiple disease-causing
          antigens with a single biologic agent. This technology could lead
          to combination biologics for complex conditions such as cancer or
          rheumatoid arthritis, where multiple pathways are involved in the
          disease.
  --  Hepatitis C
      --  Abbott's antiviral program is focused on the treatment of
          hepatitis C, a disease that affects more than 180 million people
          worldwide, with approximately 3 to 4 million people newly infected
          each year. Abbott's broad-based hepatitis C program includes our
          partnership with Enanta Pharmaceuticals to develop protease
          inhibitors, as well as our internal polymerase inhibitor program.
          Our compounds in development have the potential to shorten
          treatment duration, improve tolerability and increase cure rates.
          Abbott has three HCV compounds in human trials, with additional
          pre-clinical compounds in development. Abbott is well positioned
          to explore combinations of these new therapies, which may provide
          additional benefit to patients with HCV infection.
  --  Vascular Devices
      --  XIENCE PRIME - Abbott's next-generation DES that capitalizes on
          the proven attributes of XIENCE V while offering a novel stent
          design and a modified delivery system for improved deliverability.
          We recently received CE Mark for XIENCE PRIME in Europe.
      --  XIENCE Nano - XIENCE V for small vessels in the United States.
          This 2.25 mm diameter stent has been available in Europe since
          early 2008.
      --  Bioabsorbable DES - DES that is gradually absorbed into the vessel
          wall - much like sutures are absorbed after healing a wound - with
          the potential to return the vessel to full motion. Abbott has the
          most advanced bioabsorbable DES clinical program, with an
          opportunity to reach the market years ahead of competitors.
      --  Core products - Devices in active development include a
          next-generation bare metal stent, frontline and high-pressure
          balloons, and new guidewires.

      --  Endovascular products - Self-expanding and balloon-expanding
          peripheral stents, including the Absolute Pro and Omnilink Elite
          Peripheral Stent Systems, and the Emboshield Nav6 Embolic
          Protection Device for carotid stenting.

Source: Abbott

CONTACT: Financial, John Thomas, +1-847-938-2655, or Larry Peepo, +1-847-935-6722, or Tina Ventura, +1-847-935-9390, or Media, Melissa Brotz, +1-847-935-3456, or Scott Stoffel, +1-847-936-9502, all of Abbott

Web Site: http://www.abbott.com/

Posted: July 2009


View comments

Hide
(web4)